| Literature DB >> 9336021 |
M McIntyre1, S E Caffe, R A Michalak, J L Reid.
Abstract
Losartan potassium, an angiotensin II receptor antagonist, is the first of a new class of agents to be introduced for the treatment of hypertension. In this review, we describe the clinical pharmacology of losartan, including its pharmacokinetics in healthy, male volunteers and special patient groups, such as the elderly, patients with liver disease and patients with renal impairment. We also review its pharmacodynamics, including safety and tolerability; specificity of action; and the effect of salt depletion. We then review the studies examining clinical efficacy and safety in hypertension.Entities:
Mesh:
Substances:
Year: 1997 PMID: 9336021 DOI: 10.1016/s0163-7258(97)82002-5
Source DB: PubMed Journal: Pharmacol Ther ISSN: 0163-7258 Impact factor: 12.310